Crystalline salt of psilocin
Patent Information
- Application Number
- JP2023573066
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-02-16
- Filing Date
- 2022-05-24
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2042-05-24
Smart Images

Figure 0007594330000026 
Figure 0007594330000027 
Figure 0007594330000028
Abstract
Description
[Technical field]
[0001] The present invention relates to crystalline salts of psilocin and methods for their preparation. The present invention also relates to beneficial therapeutic uses of the crystalline salts and compositions comprising the crystalline salt forms. [Background technology]
[0002] Crystalline forms of therapeutic agents have been used to alter the physicochemical properties of drugs. Each crystalline form of a drug may have different solid-state (physical and chemical) properties that may be relevant for drug delivery. Crystalline forms often have superior chemical and physical properties than their non-crystalline counterparts, such as amorphous forms. The differences in physical properties exhibited by novel solid forms of a drug (e.g., salts, polymorphs, or cocrystals) affect pharmaceutical parameters such as melting point, storage stability, compressibility, and density (relevant for formulation and product manufacturing), as well as dissolution rate and solubility (relevant factors in achieving adequate bioavailability). For many oral drugs, a step of obtaining a suitable crystalline form of the drug is often required. For certain drugs, a suitable crystalline form provides the desired properties. Such a suitable crystalline form may be obtained by forming a salt between an ionizable drug and a suitable acid / base. Salts often have more favorable pharmaceutical and pharmacological properties than the known form of the drug itself and may be easier to process. For example, salts may have different dissolution characteristics and solubility than the drug. Furthermore, salts may be used as convenient vehicles for drug delivery, and new formulations containing salts of a given drug may have superior properties, for example, by improving processing or handling characteristics, favorably changing the dissolution profile, or improving stability or shelf life, compared to existing formulations of the drug. Similarly, salt formation is one way to avoid polymorph formation of the drug.
[0003] A drug salt (nutraceutical ingredient or active pharmaceutical ingredient) is a unique chemical composition that results when an ionizable drug combines with a counterion (acid or base) to form a charge-neutral complex. Generally, salts, when combined, have unique crystallographic and spectroscopic properties compared to the individual drug and counterion (acid or base). In a salt, the drug and counterion have unique lattice positions within the unit cell of the crystal lattice. The crystallographic properties of salts can be analyzed in the same way as other crystalline forms, using techniques such as X-ray powder diffraction (XRPD), among others. Salts often also exhibit unique thermal behavior compared to other forms of the corresponding drug. Thermal behavior can be analyzed by techniques such as capillary melting point, thermogravimetric analysis (TGA), and differential scanning calorimetry (DSC). These techniques can be used to identify and characterize salts. For pharmaceutical products ultimately destined for market, the incorporation of suitable counterions (acids or bases) with acceptable toxicity profiles must be considered when designing salts. In the pharmaceutical industry, counterions (acids or bases) are usually selected from pharma- ceutically acceptable salt forms, i.e., from the Generally Regarded as Safe (GRAS) and / or All Substances Used in Food in the United States (EAFUS) lists, due to previous FDA-approved drugs or molecules present in food. The use of naturally occurring compounds as counterions (acids or bases) expands the list of candidate molecules available to the pharmaceutical industry and provides additional physiological benefits to the consumer.
[0004] Psilocin (also known as 4-hydroxy-DMT, 4-OH-DMT, or 4-hydroxy-N,N-dimethyltryptamine) is a tryptamine alkaloid with CAS number 520-53-6, and is a hallucinogenic substance. Most magic mushrooms contain it and its phosphorylated counterpart, psilocybin. In fact, when ingested, psilocybin is rapidly metabolized to psilocin, which acts on serotonin receptors in the prefrontal cortex. The psychoactive effects of psilocin usually last for 1-3 hours, but because the drug distorts the perception of time, people under its influence may feel that the effects last much longer. Psilocin has low toxicity, does not significantly affect dopamine receptors, and reports of lethal doses of the drug are rare. Psilocin as a therapeutic agent may be suitable for treating diseases or disorders, or symptoms of diseases or disorders, such as anxiety, depression, psychotic disorders, schizophrenia, major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder, headaches, and withdrawal from opioids, cocaine, heroin, amphetamines, and nicotine. One of the crystal structures of psilocin was reported in the literature by TJ Putcher and HP Weber in 1974, along with the CCDC Ref Code of PSILIN (Journal of Chemical Society, Perkin Transactions 2, Pages 946-948). In fact, the field of psilocin crystallinity appears to be a relatively unexplored area, and other psilocin crystal forms are still needed. Summary of the Invention
[0005] The present invention relates to novel syrosin salts. Specifically, the present invention relates to 1:1 syrosin benzoate; 1:1 syrosin nicotinate; 1:1 syrosin tartrate; 2:1 syrosin hemiadipate hemiacetone solvate; 1:1 syrosin fumarate; 2:1 syrosin hemifumarate; 1:1 syrosin oxalate diethyl ether and / or ethanol-containing solvate (wherein the stoichiometry of diethyl ether:ethanol:syrosin is about 0.2:0.1:1); 1:1 syrosin DL-lactate; 1:1 syrosin L-malate; and 1:1 syrosin stearate. The present invention relates to pharmaceutical compositions containing the syrosin salts of the present invention and a pharma- ceutically acceptable counterion (acid). The syrosin salts can be used in the same manner as syrosin. As a therapeutic agent, psilocin may be suitable for treating diseases or disorders, or symptoms of diseases or disorders, such as anxiety, depression, psychotic disorders, schizophrenia, major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder, headaches, and withdrawal from opioids, cocaine, heroin, amphetamines, and nicotine, as described above. The molecular structure of psilocin is shown below. [ka] Silosin The present invention further relates to a method of treating a disease, disorder, or condition with psilocin, the improvement comprising administering to a patient in need thereof a beneficial or therapeutically effective amount of psilocin, a composition, or a pharmaceutical composition of the present invention. Yet another aspect of the present invention may be as follows. [1] A salt or cocrystal of psilocin (4-hydroxy-N,N-dimethyltryptamine) which exists in crystalline form; (a) a salt or co-crystal of benzoic acid and psilocin; (b) a salt or co-crystal of nicotinic acid and psilocin; (c) a salt or cocrystal of tartaric acid and psilocin; (d) Acetone solvate of a salt or cocrystal of adipic acid and psilocin; (e) a salt or co-crystal of fumaric acid and psilocin; (f) diethyl ether and / or ethanol containing solvates of salts or co-crystals of oxalic acid and psilocin; (g) a salt or cocrystal of lactic acid and psilocin; (h) Salts or co-crystals of malic acid and psilocin; and (i) Salt or cocrystal of stearic acid and psilocin A salt or co-crystal selected from the group consisting of: [2] The crystal form is (a) a salt or co-crystal of benzoic acid and psilocin having a stoichiometry of about 1:1; (b) a salt or co-crystal of nicotinic acid and psilocin having a stoichiometry of about 1:1; (c) a salt or co-crystal of L-(+)-tartaric acid and psilocin having a stoichiometry of about 1:1; (d) hemiacetone solvate of a hemi-salt or co-crystal of adipic acid and psilocin having a stoichiometry of about 1:2; (e)(i) a salt or co-crystal of fumaric acid and psilocin having a stoichiometry of about 1:1; (e)(ii) a hemi-salt or co-crystal of fumaric acid and psilocin having a stoichiometry of about 2:1; (f) a diethyl ether / ethanol containing solvate of a salt or co-crystal of oxalic acid and psilocin having a stoichiometry of about 1:1, wherein the stoichiometry of diethyl ether:ethanol:psilocin is about 0.2:0.1:1; (g) a salt or co-crystal of DL-lactic acid and psilocin having a stoichiometry of about 1:1; (h) a salt or co-crystal of L-malic acid and psilocin having a stoichiometry of about 1:1; and (i) A salt or co-crystal of stearic acid and psilocin having a stoichiometry of about 1:1 The salt or cocrystal according to [1] above, selected from the group consisting of: [3] The salt or co-crystal of [1] above, wherein the crystalline form is (a) a salt or co-crystal of benzoic acid and psilocin, and the crystalline form exhibits an X-ray powder diffraction pattern having at least three peaks at the following 2θ diffraction angles: 9.4, 12.3, 14.5, 16.3, 16.4, 18.1, 18.9, 19.2, 19.7, 21.3, 22.6, 22.9, 24.7, 24.8, and 26.0°2θ±0.2°2θ. [4] The salt or co-crystal according to [3] above, wherein the crystalline form has an X-ray powder diffraction pattern substantially similar to that shown in FIG. [5] The crystalline form comprises a crystal having unit cell parameters substantially equal to: TIFF0007594330000002.tif54170 The salt or cocrystal according to [3] above. [6] The crystalline form has the following characteristics: an endothermic event with a peak maximum at about 237°C as measured by differential scanning calorimetry; A thermogravimetric analysis thermogram substantially similar to that shown in FIG. 4; or A solution containing one or more peaks at approximately 2.8 ppm, 3.3 ppm, 3.4 ppm, 6.4 ppm, 6.8 ppm, 6.9 ppm, 7.0 ppm, 7.3 ppm, 7.4 ppm, or 8.0 ppm. 1 H NMR spectrum The salt or cocrystal according to [3] above, further comprising one or more of: [7] The salt or co-crystal according to [6] above, wherein the crystalline form has a differential scanning calorimetry thermogram substantially similar to that shown in FIG. [8] A solution in which the crystalline form contains characteristic peaks at at least about 6.4 ppm and about 8.0 ppm. 1 The salt or cocrystal according to [6] above, having a H NMR spectrum. [9] The crystal form is substantially the same as that shown in FIG. 1 The salt or cocrystal according to [6] above, having a H NMR spectrum.
[10] The salt or co-crystal of nicotinic acid and psilocin according to [1] above, wherein the crystalline form is (b) a salt or co-crystal of nicotinic acid and psilocin that exhibits an X-ray powder diffraction pattern having at least three peaks at the following 2θ diffraction angles: 10.2, 11.4, 12.4, 14.0, 15.1, 15.6, 17.2, 17.5, 18.4, 19.2, 20.0, 22.4, 23.5, 24.1, 25.0, and 25.2°2θ±0.2°2θ.
[11] The salt or co-crystal according to
[10] above, wherein the crystalline form has an X-ray powder diffraction pattern substantially similar to that shown in FIG.
[12] The crystalline form comprises a crystal having unit cell parameters substantially equal to: TIFF0007594330000003.tif55170 The salt or cocrystal according to
[10] above.
[13] The crystalline form has the following characteristics: an endothermic event with a peak maximum at about 189°C as measured by differential scanning calorimetry; A thermogravimetric analysis thermogram substantially similar to that shown in FIG. 9; or A solution containing one or more peaks at approximately 2.9 ppm, 3.3 ppm, 3.5 ppm, 6.4 ppm, 6.8 ppm, 6.9 ppm, 7.0 ppm, 7.4 ppm, 8.3 ppm, 8.5 ppm, or 9.1 ppm. 1 H NMR spectrum The salt or cocrystal according to
[10] , further comprising one or more of:
[14] The salt or co-crystal according to
[13] above, wherein the crystalline form has a differential scanning calorimetry thermogram substantially similar to that shown in FIG. 〔15〕 A solution in which the crystalline form contains characteristic peaks at at least about 6.4 ppm and about 9.1 ppm. 1 The salt or cocrystal according to
[13] above, having a H NMR spectrum.
[16] The crystal form is substantially the same as that shown in FIG. 1 The salt or cocrystal according to
[13] above, having a H NMR spectrum.
[17] The salt or co-crystal of [1] above, wherein the crystalline form is (c) a salt or co-crystal of tartaric acid and psilocin that exhibits an X-ray powder diffraction pattern having at least three peaks at the following 2θ diffraction angles: 13.4, 14.7, 15.9, 17.2, 18.8, 20.2, 20.8, 21.8, 22.6, 23.4, 24.6, 24.8, 25.5, and 26.6 °2θ±0.2 °2θ.
[18] The salt or co-crystal according to
[17] above, wherein the crystalline form has an X-ray powder diffraction pattern substantially similar to that shown in FIG.
[19] The crystalline form comprises a crystal having unit cell parameters substantially equal to: TIFF0007594330000004.tif54170 The salt or cocrystal according to
[17] above.
[20] The crystalline form has the following characteristics: an endothermic event with a peak maximum at about 167° C. as measured by differential scanning calorimetry; A thermogravimetric analysis thermogram substantially similar to that shown in FIG. 14; or A solution containing one or more peaks at approximately 2.9 ppm, 3.3 ppm, 3.5 ppm, 4.4 ppm, 6.4 ppm, 6.9 ppm, or 7.0 ppm. 1 H NMR spectrum The salt or cocrystal according to
[17] , further comprising one or more of:
[21] The salt or co-crystal according to
[20] above, wherein the crystalline form has a differential scanning calorimetry thermogram substantially similar to that shown in FIG. 13.
[22] A solution in which the crystalline form contains characteristic peaks at at least about 6.4 ppm and about 4.4 ppm. 1 The salt or cocrystal according to
[20] above, having a H NMR spectrum.
[23] The crystal form is substantially the same as that shown in FIG. 1 The salt or cocrystal according to
[20] above, having a H NMR spectrum.
[24] The salt or co-crystal according to [1] above, wherein the crystalline form is (d) an acetone solvate of a salt of adipic acid and psilocin, and the crystalline form exhibits an X-ray powder diffraction pattern having at least three peaks at the following 2θ diffraction angles: 8.4, 10.3, 10.8, 13.4, 15.0, 15.3, 15.5, 15.8, 16.9, 18.2, 20.1, 21.6, 21.8, 22.9, and 28.0°2θ±0.2°2θ.
[25] The salt or co-crystal according to
[24] above, wherein the crystalline form has an X-ray powder diffraction pattern substantially similar to that shown in FIG.
[26] The crystalline form includes crystals having unit cell parameters substantially equal to: TIFF0007594330000005.tif54170 The salt or cocrystal according to
[24] above.
[27] The crystalline form has the following characteristics: one or more endotherms having peak maxima at about 49° C., 102° C., 135° C., 155° C., or 179° C. as measured by differential scanning calorimetry; A thermogravimetric analysis thermogram substantially similar to that shown in FIG. 19; or A solution containing one or more peaks at approximately 1.6 ppm, 1.7 ppm, 2.2 ppm, 2.3 ppm, 2.8 ppm, 3.2 ppm, 3.3 ppm, 6.4 ppm, 6.8 ppm, 6.9 ppm, or 7.0 ppm. 1 H NMR spectrum The salt or cocrystal according to
[24] , further comprising one or more of:
[28] The salt or cocrystal according to
[27] , wherein the crystalline form has a differential scanning calorimetry thermogram substantially similar to that shown in FIG. 18.
[29] A solution in which the crystalline form contains characteristic peaks at at least about 6.4 ppm and at about 1.6 to 1.7 ppm. 1 The salt or cocrystal according to
[27] above, having a H NMR spectrum.
[30] The crystal form is substantially the same as that shown in FIG. 1 The salt or cocrystal according to
[27] above, having a H NMR spectrum.
[31] The salt or co-crystal of [1] above, wherein the crystalline form is (e) a salt or co-crystal of fumaric acid and psilocin, and the crystalline form exhibits an X-ray powder diffraction pattern with at least three peaks at the following 2θ diffraction angles: 6.9, 10.5, 12.2, 12.6, 15.8, 16.1, 16.7, 17.0, 18.3, 19.1, 20.3, 20.8, 22.6, 23.1, 23.3, 23.5, 24.2, 25.3, 25.9, and 27.8 °2θ±0.2 °2θ.
[32] The salt or co-crystal according to
[31] above, wherein the crystalline form has an X-ray powder diffraction pattern substantially similar to that shown in FIG. 21.
[33] The crystalline form includes crystals having unit cell parameters substantially equal to: TIFF0007594330000006.tif54170 The salt or cocrystal according to
[31] above.
[34] The crystalline form has the following characteristics: an endothermic event with a peak maximum at about 167° C. as measured by differential scanning calorimetry; A thermogravimetric analysis thermogram substantially similar to that shown in FIG. 24; or A solution containing one or more peaks at approximately 2.9 ppm, 3.3 ppm, 3.5 ppm, 6.4 ppm, 6.7 ppm, 6.8 ppm, 6.9 ppm, or 7.0 ppm. 1 H NMR spectrum The salt or cocrystal according to
[31] , further comprising one or more of:
[35] The salt or co-crystal according to
[34] , wherein the crystalline form has a differential scanning calorimetry thermogram substantially similar to that shown in FIG. 23.
[36] A solution in which the crystalline form contains characteristic peaks at at least about 6.4 ppm and about 6.7 ppm. 1 The salt or cocrystal according to
[34] above, having a H NMR spectrum.
[37] The crystal form is substantially the same as that shown in FIG. 1 The salt or cocrystal according to
[34] above, having a H NMR spectrum.
[38] The salt or co-crystal described in [1] above, wherein the crystalline form is (e) a salt or co-crystal of fumaric acid and psilocin, and the crystalline form exhibits an X-ray powder diffraction pattern having at least three peaks at the following 2θ diffraction angles: 9.7, 13.7, 16.1, 16.6, 23.9, 24.7, and 25.2 °2θ ± 0.2 °2θ.
[39] The salt or co-crystal according to
[38] above, wherein the crystalline form has an X-ray powder diffraction pattern substantially similar to that shown in FIG. 26.
[40] The crystalline form includes crystals having unit cell parameters substantially equal to: TIFF0007594330000007.tif55170 The salt or cocrystal according to
[38] above.
[41] The crystalline form has the following characteristics: an endothermic event with a peak maximum at about 225°C as measured by differential scanning calorimetry; A thermogravimetric analysis thermogram substantially similar to that shown in FIG. 29; or A solution containing one or more peaks at approximately 2.8 ppm, 3.3 ppm, 3.4 ppm, 6.4 ppm, 6.7 ppm, 6.8 ppm, 6.9 ppm, or 7.0 ppm. 1 H NMR spectrum The salt or cocrystal according to
[38] , further comprising one or more of:
[42] The salt or co-crystal according to
[41] , wherein the crystalline form has a differential scanning calorimetry thermogram substantially similar to that shown in FIG. 28.
[43] A solution in which the crystalline form contains characteristic peaks at at least about 6.4 ppm and about 6.7 ppm. 1 The salt or cocrystal according to
[41] above, having a H NMR spectrum.
[44] The crystal form is substantially the same as that shown in FIG.1 The salt or cocrystal according to
[41] above, having a H NMR spectrum.
[45] The salt or co-crystal according to [1] above, wherein the crystalline form is (f) a diethyl ether and / or ethanol-containing solvate of a salt or co-crystal of oxalic acid and psilocin, and the crystalline form exhibits an X-ray powder diffraction pattern having at least three peaks at the following 2θ diffraction angles: 7.6, 7.8, 10.3, 14.2, 15.3, 15.7, 17.1, 19.5, 20.4, 20.6, 21.0, 21.7, 22.9, 23.7, 24.1, 24.3, 24.8, and 27.1 °2θ±0.2 °2θ.
[46] The salt or co-crystal according to
[45] above, wherein the crystalline form has an X-ray powder diffraction pattern substantially similar to that shown in FIG.
[47] The crystalline form includes crystals having unit cell parameters substantially equal to: TIFF0007594330000008.tif54170 The salt or cocrystal according to
[45] above.
[48] The crystalline form has the following characteristics: an endothermic event with a peak maximum at about 119°C as measured by differential scanning calorimetry; A thermogravimetric analysis thermogram substantially similar to that shown in FIG. 34; or A solution containing one or more peaks at approximately 2.9 ppm, 3.3 ppm, 3.5 ppm, 6.4 ppm, 6.8 ppm, 6.9 ppm, or 7.0 ppm. 1 H NMR spectrum The salt or cocrystal according to
[45] , further comprising one or more of:
[49] The salt or co-crystal according to
[48] , wherein the crystalline form has a differential scanning calorimetry thermogram substantially similar to that shown in Figure 33.
[50] The crystal form is substantially the same as that shown in FIG. 1 The salt or cocrystal according to
[48] above, having a H NMR spectrum.
[51] The salt or co-crystal of [1] above, wherein the crystalline form is a salt or co-crystal of lactic acid and psilocin that exhibits an X-ray powder diffraction pattern having at least three peaks at the following 2θ diffraction angles: 9.0, 13.8, 14.4, 15.6, 17.8, 18.4, 20.3, 21.7, 22.3, 22.9, 24.0, and 25.5°2θ±0.2°2θ.
[52] The salt or co-crystal according to
[51] above, wherein the crystalline form has an X-ray powder diffraction pattern substantially similar to that shown in FIG.
[53] The crystalline form includes crystals having unit cell parameters substantially equal to: TIFF0007594330000009.tif54170 The salt or cocrystal according to
[51] above.
[54] The crystalline form has the following characteristics: an endothermic event with a peak maximum at about 148° C. as measured by differential scanning calorimetry; A thermogravimetric analysis thermogram substantially similar to that shown in FIG. 39; or A solution containing one or more peaks at approximately 1.2 ppm, 2.3 ppm, 2.7 ppm, 2.9 ppm, 3.9 ppm, 6.3 ppm, 6.7 ppm, 6.8 ppm, 6.9 ppm, or 10.6 ppm. 1 H NMR spectrum The salt or cocrystal according to
[51] , further comprising one or more of:
[55] The salt or co-crystal according to
[54] , wherein the crystalline form has a differential scanning calorimetry thermogram substantially similar to that shown in Figure 38.
[56] A solution in which the crystalline form contains characteristic peaks at at least about 1.2 ppm and about 6.3 ppm. 1 The salt or cocrystal according to
[54] above, having a H NMR spectrum.
[57] The crystal form is substantially the same as that shown in FIG. 1 The salt or cocrystal according to
[54] above, having a H NMR spectrum.
[58] The salt or co-crystal of [1] above, wherein the crystalline form is a salt or co-crystal of malic acid and psilocin that exhibits an X-ray powder diffraction pattern having at least three peaks at the following 2θ diffraction angles: 8.6, 9.0, 11.7, 12.6, 15.9, 16.8, 18.1, 20.2, 20.6, 21.4, 22.8, 26.1, and 28.0°2θ±0.2°2θ.
[59] The salt or co-crystal according to
[58] above, wherein the crystalline form has an X-ray powder diffraction pattern substantially similar to that shown in FIG.
[60] The crystalline form includes crystals having unit cell parameters substantially equal to: TIFF0007594330000010.tif54170 The salt or cocrystal according to
[58] above.
[61] The crystalline form has the following characteristics: an endothermic event with a peak maximum at about 129°C as measured by differential scanning calorimetry; A thermogravimetric analysis thermogram substantially similar to that shown in FIG. 44; or A solution containing one or more peaks at approximately 2.3 ppm, 2.7 ppm, 3.1 ppm, 3.9 ppm, 6.3 ppm, 6.8 ppm, 7.0 ppm, or 10.7 ppm. 1 H NMR spectrum The salt or cocrystal according to
[58] , further comprising one or more of:
[62] The salt or co-crystal according to
[61] , wherein the crystalline form has a differential scanning calorimetry thermogram substantially similar to that shown in Figure 43.
[63] A solution in which the crystalline form contains characteristic peaks at at least about 6.3 ppm and about 3.9 ppm. 1 The salt or cocrystal according to
[61] above, having a H NMR spectrum.
[64] The crystal form is substantially the same as that shown in FIG. 1 The salt or cocrystal according to
[61] above, having a H NMR spectrum.
[65] The salt or co-crystal of [1] above, wherein the crystalline form is (i) a salt or co-crystal of stearic acid and psilocin that exhibits an X-ray powder diffraction pattern having at least three peaks at the following 2θ diffraction angles: 4.5, 8.9, 14.4, 15.6, 20.1, 21.0, 23.9, and 26.4°2θ±0.2°2θ.
[66] The salt or co-crystal according to
[65] above, wherein the crystalline form has an X-ray powder diffraction pattern substantially similar to that shown in FIG.
[67] The crystalline form comprises a crystal having unit cell parameters substantially equal to: TIFF0007594330000011.tif54170 The salt or cocrystal according to
[65] above.
[68] The crystalline form has the following characteristics: an endothermic event with a peak maximum at about 86° C. as measured by differential scanning calorimetry; A thermogravimetric analysis thermogram substantially similar to that shown in FIG. 49; or A solution containing one or more peaks at approximately 0.9 ppm, 1.2 ppm, 1.5 ppm, 2.2 ppm, 2.6 ppm, 2.9 ppm, 6.3 ppm, 6.7 ppm, 6.8 ppm, 6.9 ppm, and 10.6 ppm. 1 H NMR spectrum The salt or cocrystal according to
[65] , further comprising one or more of:
[69] The salt or co-crystal according to
[68] , wherein the crystalline form has a differential scanning calorimetry thermogram substantially similar to that shown in Figure 48.
[70] A solution in which the crystalline form contains characteristic peaks at at least about 6.3 ppm and about 0.9 ppm. 1 The salt or cocrystal according to
[68] above, having a H NMR spectrum.
[71] The crystal form is substantially the same as that shown in FIG. 1 The salt or cocrystal according to
[68] above, having a H NMR spectrum.
[72] A pharmaceutical composition comprising the salt or cocrystal according to [1] above and at least one pharma- ceutically acceptable carrier.
[73] The pharmaceutical composition according to
[72] , wherein the pharmaceutical composition is an oral formulation.
[74] The pharmaceutical composition according to
[73] , wherein the pharmaceutical composition is an oral solid dosage form.
[75] A method for preparing the salt or co-crystal described in [1] above, comprising reacting psilocin with an acid selected from the group consisting of benzoic acid, nicotinic acid, tartaric acid, adipic acid, fumaric acid, oxalic acid, lactic acid, malic acid, and stearic acid, to precipitate a salt or co-crystal of psilocin with the respective acid in crystalline form.
[76] The method according to
[75] , further comprising dissolving, suspending or grinding the silosin and / or acid in an organic solvent selected from the group consisting of alcohols, ethers, ketones, alkanes, and mixtures thereof.
[77] The method according to
[76] , wherein the organic solvent is diethyl ether, isopropyl alcohol, acetone, ethanol, methyl ethyl ketone, tert-butyl ether, hexane, or a mixture thereof.
[78] A method for treating a disease or disorder in a subject for which psilocin or psilocybin is indicated, comprising administering to the subject in need thereof a therapeutically effective amount of the salt or cocrystal described in [1].
[79] The method according to
[78] , wherein the disease or disorder is a psychiatric or psychotic disorder, a neurocognitive disease or disorder, an autism spectrum disorder (ASD), chronic pain, an inflammatory disease or disorder, stroke, an epilepsy disorder, amyotrophic lateral sclerosis (ALS), or a combination thereof.
[80] The method according to
[79] , wherein the disease or disorder is a mental disorder or psychotic disorder selected from the group consisting of attention deficit hyperactivity disorder (ADHD), anxiety disorder, sleep-wake disorder, impulse control disorder, disruptive behavior disorder, conduct disorder, depressive disorder, major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder and related disorders, bipolar disorder, schizophrenia, and combinations thereof.
[81] The method according to
[79] above, wherein the disease or disorder is a neurocognitive disease or disorder selected from the group consisting of Alzheimer's disease; dementia with Lewy bodies; traumatic brain injury; prion disease; HIV infection; Parkinson's disease; Huntington's disease; conditions or situations related to alcohol, smoking, or drugs; and combinations thereof. [Brief description of the drawings]
[0006] [Figure 1] 1 is a graph showing the XRPD pattern of 1:1 psilocin benzoate 1. [Diagram 2] FIG. 1 is a graph showing indexing of the XRPD pattern of 1:1 psilocin benzoate 1. [Diagram 3] 1 is a graph showing a DSC trace of 1:1 psilocin benzoate 1. [Figure 4] 1 is a graph showing a TGA trace of 1:1 psilocin benzoate 1. [Diagram 5] 1 is a graph showing the H NMR spectrum of 1:1 psilocin benzoate 1. [Figure 6] 1 is a graph showing the XRPD pattern of 1:1 psilocin nicotinate 2. [Figure 7] FIG. 1 is a graph showing indexing of the XRPD pattern of 1:1 psilocin nicotinate 2. [Figure 8] 1 is a graph showing a DSC trace of 1:1 psilocin nicotinate 2. [Figure 9] 1 is a graph showing a TGA trace of 1:1 psilocin nicotinate 2. [Figure 10] 1 is a graph showing the H NMR spectrum of 1:1 psilocin nicotinate 2. [Figure 11] 1 is a graph showing the XRPD pattern of 1:1 psilocin tartrate 3. [Figure 12] FIG. 1 is a graph showing indexing of the XRPD pattern of 1:1 psilocin tartrate 3. [Figure 13] 1 is a graph showing a DSC trace of 1:1 psilocin tartrate 3. [Figure 14] 1 is a graph showing a TGA trace of 1:1 psilocin tartrate 3. [Figure 15] 1 is a graph showing the H NMR spectrum of 1:1 psilocin tartrate 3. [Figure 16]1 is a graph showing the XRPD pattern of the 2:1 psirosin hemiadipate 4 hemiacetone solvate. [Figure 17] FIG. 1 is a graph showing the indexing of the XRPD pattern of the 2:1 psirosin hemiadipate 4 hemiacetone solvate. [Figure 18] 1 is a graph showing a DSC trace of the hemiacetone solvate of 2:1 psirosin hemiadipate 4. [Figure 19] 1 shows a TGA trace of the hemiacetone solvate of 2:1 psirosin hemiadipate 4. [Figure 20] 1 is a graph showing the H NMR spectrum of the 2:1 psilocin hemiadipate 4 hemiacetone solvate. [Figure 21] 1 is a graph showing the XRPD pattern of 1:1 psilocin fumarate 5. [Figure 22] 1 is a graph showing the indexing of the XRPD pattern of 1:1 psilocin fumarate 5. [Diagram 23] 1 is a graph showing a DSC trace of 1:1 psirosin fumarate 5. [Figure 24] 1 is a graph showing a TGA trace of 1:1 silosin fumarate 5. [Diagram 25] 1 is a graph showing the H NMR spectrum of 1:1 psilocin fumarate 5. [Figure 26] FIG. 1 shows the XRPD pattern of 2:1 psilocin hemifumarate 6. [Figure 27] FIG. 1 is a graph showing indexing of the XRPD pattern of 2:1 psilocin hemifumarate 6. [Figure 28] 1 is a graph showing a DSC trace of 2:1 psilocin hemifumarate 6. [Figure 29] 1 is a graph showing a TGA trace of 2:1 psilocin hemifumarate 6. [Diagram 30] FIG. 1 is a graph showing the H NMR spectrum of 2:1 psilocin hemifumarate 6. [Diagram 31]FIG. 1 is a graph showing the XRPD pattern of the 1:1 psilocin oxalate 7 solvate. [Diagram 32] FIG. 1 is a graph showing the indexing of the XRPD pattern of the 1:1 psilocin oxalate 7 solvate. [Diagram 33] FIG. 1 shows a DSC trace of a 1:1 psilocin oxalate 7 solvate. [Diagram 34] FIG. 1 shows a TGA trace of a 1:1 psilocin oxalate 7 solvate. [Diagram 35] FIG. 1 is a graph showing the H NMR spectrum of the 1:1 psilocin oxalate 7 solvate. [Diagram 36] 1 is a graph showing the XRPD pattern of 1:1 psilocin DL-lactate 8. [Figure 37] 1 is a graph showing the indexing of the XRPD pattern of 1:1 psilocin DL-lactate 8. [Figure 38] 1 is a graph showing a DSC trace of 1:1 psilocin DL-lactate 8. [Figure 39] 1 is a graph showing a TGA trace of 1:1 psilocin DL-lactate 8. [Diagram 40] 1 is a graph showing the H NMR spectrum of 1:1 psilocin DL-lactate 8. [Diagram 41] 1 is a graph showing the XRPD pattern of 1:1 psilocin L-malate 9. [Diagram 42] FIG. 1 is a graph showing indexing of the XRPD pattern of 1:1 psilocin L-malate 9. [Diagram 43] 1 is a graph showing a DSC trace of 1:1 psilocin L-malate 9. [Diagram 44] 1 is a graph showing a TGA trace of 1:1 psilocin L-malate 9. [Diagram 45] 1 is a graph showing the H NMR spectrum of 1:1 psilocin L-malate 9. [Diagram 46] 1 is a graph showing the XRPD pattern of 1:1 syrosin stearate 10. [Figure 47]1 is a graph showing the indexing of the XRPD pattern of 1:1 Syrosin stearate 10. [Figure 48] 1 is a graph showing the DSC trace of 1:1 syrosin stearate 10. [Figure 49] 1 is a graph showing a TGA trace of 1:1 syrosine stearate 10. [Figure 50] 1 is a graph showing the H NMR spectrum of 1:1 syrosine stearate 10. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0007] The present invention relates to novel crystalline salt forms of psilocin. The crystalline salts, 1:1 psilocin benzoate, 1:1 psilocin nicotinate, 1:1 psilocin tartrate, 2:1 psilocin hemiadipate hemiacetone solvate, 1:1 psilocin fumarate, 2:1 psilocin hemifumarate, 1:1 psilocin oxalate solvate, 1:1 psilocin DL-lactate, 1:1 psilocin L-malate, and 1:1 psilocin stearate, have been prepared and characterized by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and solution proton nuclear magnetic resonance (NMR) as described in the Examples below. 1 The compound was characterized by 1 H NMR.
[0008] Therapeutic Uses of Crystalline Psilocin Forms Psilocin (also known as 4-hydroxy-DMT, 4-OH-DMT, or 4-hydroxy-N,N-dimethyltryptamine) is known to be beneficial to human health. The present invention also provides beneficial therapeutic uses of silocin salts and methods of delivery thereof, as well as compositions, such as pharmaceutical dosage forms, containing crystalline silocin salts, in humans. Furthermore, the crystalline silocin salts of the present invention can be used to treat diseases, disorders, and conditions such as those mentioned above, and provide beneficial treatments to humans. Additionally, the present invention relates to a method of treating such a disease, disorder, or condition, comprising administering to a patient in need thereof a beneficial or therapeutically effective amount of the crystalline psilocin salt, composition, or pharmaceutical composition of the present invention.Similarly, the present invention relates to the use of psilocin to treat a disease, disorder, or condition, comprising administering to a patient in need thereof a beneficial or therapeutically effective amount of the crystalline psilocin salt, composition, or pharmaceutical composition of the present invention. The present invention also relates to a method of treating (or using a psilocin salt to treat) such disease, disorder, or condition by administering a therapeutically effective or beneficial amount of the crystalline psilocin salt of the present invention to a human or animal patient in need thereof, or a method of administering a therapeutic composition containing the crystalline psilocin of the present invention to a human or animal patient in need thereof. The term "treatment" or "treating" refers to any treatment of a disease, disorder, or condition in a mammal, including preventing or protecting against the disease, disorder, or condition, i.e., preventing clinical symptoms from developing; inhibiting the disease, disorder, or condition, i.e., arresting or suppressing the development of clinical symptoms; and / or relieving the disease, disorder, or condition (including reducing the discomfort associated with the condition or disorder), i.e., causing clinical symptoms to regress. Those skilled in the art will appreciate that in human medicine, a distinction between "prevention" and "suppression" is not always possible, since one or more of the eventual initiating events may be unknown and subclinical, or the patient may not be identified until long after the occurrence of the event. Thus, as used herein, the term "prophylaxis" is intended as a component of "treatment" that encompasses both "preventing" and "suppressing" a disease, disorder, or condition. The term "protection" is intended to include "prophylaxis." The crystalline psilocin salts of the present invention may be administered once or multiple times daily at a psilocin dosage of about 0.001 to about 1.0 mg / kg of subject body weight / day, about 0.01 to about 0.5 mg / kg of subject body weight / day, or about 0.1 to about 0.20 mg / kg of subject body weight / day to achieve the desired effect. It will be appreciated that, where appropriate, doses below 0.001 mg / kg or above 1.0 mg / kg (e.g., 1 to 2 mg / kg) may be administered to subjects in need thereof.
[0009] Compositions containing crystalline silosin salts The present invention also relates to compositions, such as dietary supplements and pharmaceutical compositions, comprising a beneficial or therapeutically effective amount of a crystalline silosin salt according to the present invention and a carrier, such as a pharma- ceutically acceptable carrier (also known as a pharma- ceutically acceptable excipient). The compositions and pharmaceutical dosage forms may be administered in any amount, in any form of composition, dietary supplement or pharmaceutical composition, and using any route of administration that is beneficial or therapeutically effective for treatment. As mentioned above, these pharmaceutical compositions are therapeutically useful for treating or preventing disorders such as those mentioned above. The pharmaceutical composition of the present invention may be any pharmaceutical dosage form known in the art containing the crystalline silosin salt according to the present invention. The composition, particularly the pharmaceutical composition, may be, for example, a tablet, a capsule, a liquid suspension, an injectable composition, a topical composition, an inhalation composition, or a transdermal composition. The composition, particularly the pharmaceutical composition, generally contains, for example, about 0.1 to about 99.9% by weight of the crystalline silosin salt, for example, about 0.5 to about 99% by weight of the crystalline silosin salt of the present invention, and, for example, 99.5 to 0.5% by weight of at least one suitable pharma- ceutically acceptable carrier and / or excipient. The composition may also be about 5 to about 75% by weight of the crystalline silosin salt of the present invention, with the remainder being at least one suitable pharma-ceutically acceptable carrier and / or excipient, as described below. The formulation will include suitable pharma- ceutically acceptable carriers and / or excipients in the desired dosage, as known to those skilled in the art.The pharmaceutical compositions of the present disclosure can be administered to humans and other animals orally, rectally, parenterally, intravenously, intracisternally, intravaginally, intraperitoneally, topically (by powder, ointment, or drops), buccal, oral or nasal spray, etc., depending on the site and severity of the condition to be treated.In one embodiment, the pharmaceutical composition is in an oral unit dosage form.
[0010] Compositions, particularly pharmaceutical compositions of the present invention, include a beneficial or therapeutically effective amount of the crystalline silosin salt of the present invention and a carrier, such as a pharma- ceutically acceptable carrier and / or excipient. Such pharma-ceutically acceptable carriers and excipients include, but are not limited to, binders, fillers, lubricants, emulsifiers, suspending agents, sweeteners, flavorings, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other conventional excipients and additives. Thus, pharmaceutical compositions of the present invention may include any one or combination of the following: pharma-ceutically acceptable carriers or excipients; other medicinal agent(s); pharmaceutical agent(s); adjuvants; buffers; preservatives; diluents; and various other pharmaceutical additives and drugs known in the art. These additional formulation additives and drugs are often biologically inert and do not cause adverse side effects or interactions when administered to humans. Suitable excipients include, but are not limited to, microcrystalline cellulose, lactose, sucrose, fructose, glucose, dextrose, other sugars, dibasic calcium phosphate, calcium sulfate, cellulose, methylcellulose, cellulose derivatives, kaolin, mannitol, lactitol, maltitol, xylitol, sorbitol, other sugar alcohols, dry starch, dextrin, maltodextrin, other polysaccharides, or mixtures thereof. In one embodiment of the present invention, the pharmaceutical composition is an oral dosage unit containing a therapeutically effective amount of the crystalline silosin salt of the present invention and a pharmaceutically acceptable carrier and / or excipient.Exemplary oral dosage unit forms for use in the present disclosure include tablets, capsules, powders, suspensions, and lozenges, which can be prepared by any conventional method for preparing pharmaceuticals in oral dosage form.Oral dosage unit forms such as tablets can contain one or more pharmaceutically acceptable carriers and / or excipients known in the art, such as those described above, including but not limited to release regulators, flow agents, compression aids, disintegrants, effervescent agents, lubricants, binders, diluents, flavors, flavor enhancers, sweeteners, and preservatives. Tablet dosage forms may be partially or fully coated, multi-coated, uncoated, and may include channeling agents. The ingredients are selected from a variety of excipients known in the pharmaceutical art. Depending on the desired characteristics of the oral dosage form, any number of ingredients may be selected, alone or in combination, for known use in preparing dosage forms such as tablets. EXAMPLES
[0011] The following reagents and analytical methods were used to prepare and characterize silosin salts 1-10 of the present invention. Work was generally carried out at room temperature (RT) of about 25° C. reagent Psilocin was obtained from Cayman Chemical and used as received. All other chemicals were purchased from various commercial sources and used without purification. X-ray powder diffraction (XRPD)XRPD patterns of silosin salts 1-7 were collected on a PANalytical X'Pert PRO MPD or PANalytical Empyrean diffractometer using an incident beam of Cu radiation generated with an Optix long fine focus source. An elliptically graded multilayer mirror was used to focus the Cu Kα X-rays through the specimen and onto the detector. Prior to analysis, a silicon specimen (NIST SRM 640f) was analyzed to confirm that the observed position of the Si111 peak matched the NIST certified position. Sample specimens were sandwiched between 3 μm thick films and analyzed in transmission geometry. A beam stop, short anti-scatter extensions, and an anti-scatter knife edge were used to minimize air background. Soller slits were used for the incident and diffracted beams to minimize broadening due to axial divergence. Diffraction patterns were collected using a scanning position sensitive detector (X'Celerator) positioned 240 mm from the specimen and Data Collector software v.5.5. XRPD patterns of silosin salts 8-10 were collected on a Rigaku Smart-Lab X-ray diffraction system configured in reflection Bragg-Brentano geometry with the source X-ray beam. The X-ray source was a Cu Long Fine Focus tube operated at 40 kV and 44 mA. With this source, the incident beam profile at the sample changed from a thin line at high angles to a wide rectangle at low angles. A beam-adjusting slit was used on the X-ray source to ensure that the maximum beam size was less than 10 mm both along the line and perpendicular to the line. The Bragg-Brentano geometry is a para-focusing geometry controlled by passive divergence and receiving slits, with the sample itself acting as the focusing element of the optical system. The inherent resolution of the Bragg-Brentano geometry is influenced to some extent by the radius of the diffractometer used and the width of the receiving slit. Typically, the Rigaku Smart-Lab is operated such that the peak width is less than 0.1°2θ. The axial divergence of the X-ray beam was controlled by 5.0 degree Soller slits in both the incident and diffracted beam paths. Powder samples were prepared in a low-background silicon holder and gently pressed manually to make the sample surface flat and flush with the reference plane of the sample holder. Each sample was analyzed from 2 to 40° 2θ using a continuous scan of 6° 2θ per minute with an effective step size of 0.02° 2θ.
[0012] X-ray powder diffraction indexing Patterns of psilocin salts 1-7 were indexed using proprietary software [TRIADS® is the subject of U.S. Pat. No. 8,576,985] or X'Pert High Score Plus 2.2a (2.2.1). Patterns of psilocin salts 8-10 were indexed using TOPAS 6 (TOPAS 6.0.0.9, 2018 Bruker AXS GmbH, Karlsruhe, Germany) in conjunction with Pawley refinement. Refinement was performed using X'Pert High Score Plus 2.2a (2.2.1). 2 The indexing is performed simultaneously for all parameters until it converges to 0.001. Indexing is a method to determine the size and shape of the crystallographic unit cell from the peak positions in a diffraction pattern. It is so named because it assigns Miller index labels to each peak. If all peaks in a pattern are indexed with a single unit cell, this is strong evidence that the sample contains a single crystalline phase. Once the indexing solution is obtained, the volume of the unit cell can be calculated directly. Indexing also robustly describes the crystal morphology and succinctly summarizes all available peak positions for that phase at a particular thermodynamic state point. In the figures shown for indexed XRPD patterns, agreement of the observed peaks with the indexed accepted peak positions, marked with red bars in boxes below the XRPD pattern (shown in Figures 2, 7, 12, 17, 22, 27, and 32 for salts 1-7) or with blue tick marks on the x-axis below the XPRD pattern (shown in Figures 37, 42, and 47 for salts 8-10), indicates consistency in the unit cell determination. The space groups corresponding to the assigned annihilation symbols, unit cell parameters, and derived quantities are given in the tables below for salts 1-7 shown in Figures 2, 7, 12, 17, 22, 27, and 32, and are described below in the description of Figures 37, 42, and 47 for salts 8-10.
[0013] Differential Scanning Calorimetry (DSC) DSC analysis was performed on silosin salts 1-7 using a Mettler-Toledo DSC3+ Differential Scanning Calorimeter. Taul lag adjustments were performed with indium, tin, and zinc. Temperature and enthalpy adjustments were made with octane, phenyl salicylate, indium, tin, and zinc. Adjustments were then verified with octane, phenyl salicylate, indium, tin, and zinc. Samples were placed in sealed aluminum DSC pans, masses were accurately recorded, and samples were inserted into the DSC cell. A pre-weighed aluminum pan configured as the sample pan was placed in the reference side of the cell. Pan lids were pierced prior to sample analysis. DSC analyses were performed on silosin salts 8-10 using a TA Instruments Q2500 Discovery Series instrument. Temperature calibration of the instrument was performed with indium. The DSC cell was kept under a nitrogen purge of approximately 50 mL / min during each analysis. Samples were placed in crimped standard aluminum pans and heated at a rate of 10 °C / min from approximately 25 to 350 °C.
[0014] Thermogravimetric analysis (TGA) Thermogravimetric analysis was performed on silosin salts 1-7 using a Mettler-Toledo TGA / DSC3+ analyzer. Temperature and enthalpy adjustments were made with indium, tin, zinc, and phenyl salicylate, then verified with indium. The balance was verified with calcium oxalate. Samples were placed in aluminum pans. The pans were sealed, pierced in the lid, and then inserted into the TG furnace. A weighed aluminum pan configured as the sample pan was placed on the reference platform of the cell. The furnace was heated under nitrogen. Thermogravimetric analysis typically has an equilibration time at the beginning of each analysis, indicated by a red bracket on the thermogram. The start temperature for the associated mass loss calculations is chosen to be beyond this region (usually above 35°C) for accuracy. TGA analysis was performed on 8-10 silosin salts using a TA Instruments Q5500 Discovery Series instrument. The balance of the instrument was calibrated with M-class weights, and temperature calibration was performed using Alumel. Nitrogen purge was approximately 40 mL / min for the balance and approximately 60 mL / min for the furnace. Each sample was placed in a tared platinum pan and heated at a rate of 10 °C / min from approximately 25 to 350 °C.
[0015] solution 1 H nuclear magnetic resonance (NMR) spectroscopy Solution NMR spectra of silosin salts 1-7 were acquired using an Avance 600 MHz spectrometer. Samples were prepared by dissolving approximately 5-10 mg of sample in methanol-d4 containing TMS. Data acquisition parameters were obtained from the spectra. Solution NMR spectra of silosin salts 8-10 were acquired using a Bruker Avance II 400 spectrometer. Samples were prepared by dissolving the materials in DMSO-d6. The solutions were filtered and individually placed into 5 mm NMR tubes, and spectra were subsequently acquired. 1 H NMR spectra were acquired on an Avance II 400 using a 5 mm cryoprobe operating at an observation frequency of 400.18 MHz.
[0016] Ion Chromatography (IC) A multi-element anion standard solution (Alltech Anion Mix 5, part number: 269110, 50 μg / mL) was diluted 5 times with water to a working concentration of 2000 μg / L. Ion chromatographic analysis was performed using a Dionex ICS-5000. + The analysis was carried out using a series ion chromatograph, ICS-5000. +consists of two chromatographic systems sharing an autosampler. The system used for anion detection was equipped with a gradient pump, eluent generator module, conductivity detector, and suppressor (AERS 4 mm). A Dionex UTAC-ULP1 5 x 23 mm concentrator column was used in place of the sample loop. A Dionex IonPac® AG19 4 x 50 mm guard column and a Dionex IonPac® AS19 4 x 250 mm analytical column were installed. Water (18.2 MΩ, dispensed from an ELGA Purelab Flex2) was used to fill the eluent reservoir, prepare the standards, and wash the autosampler. DMSO was used for sample preparation and associated blank injections.
[0017] [Example 1] 1:1 Psilocin Benzoate 1 1.1 Preparation of 1:1 psilocin benzoate 1 A slightly turbid suspension of 200.0 mg psilocin (Cayman Chemical, Lot: 0594443) in 20 mL diethyl ether (Sigma Aldrich, Lot: SHBL6577) was decolorized with activated charcoal and filtered through a 0.2 μm nylon filter. Approximately half of the clear solution was added to 59.8 mg benzoic acid (Sigma Aldrich, Lot: MKCL7479). The sample was stirred by hand until a precipitate formed. The sample was allowed to stand at ambient temperature for 1 day, after which the precipitant was isolated by water suction vacuum filtration. 1.2 XRPD Characterization of 1:1 Psilocin Benzoate 1 The experimental XRPD pattern of 1:1 psilocin benzoate 1 is shown in Figure 1. Table 1 shows the angles (°2θ±0.2°2θ) and interplanar spacings of the peaks identified in the experimental XRPD pattern of Figure 1. The entire list of peaks, or a subset thereof, may be sufficient to characterize the salt, as well as an XRPD pattern substantially similar to Figure 1 (i.e., discernible within experimental variability by one skilled in the art using the present methods). For example, the 1:1 psilocin benzoate of the present invention may be characterized by a powder X-ray diffraction pattern having at least three, four, or five peaks selected from 9.4, 12.3, 14.5, 16.3, 16.4, 18.1, 18.9, 19.2, 19.7, 21.3, 22.6, 22.9, 24.7, 24.8, and 26.0°2θ±0.2°2θ. [Table 1] 1.3 Indexing of the XRPD pattern of 1:1 psilocin benzoate 1 The XRPD indexing description (Figure 2) shows a basic monoclinic crystal system with space group P21 / c(14). The unit cell parameters are a = 9.633 Å, b = 11.526 Å, c = 16.873 Å, α = 90°, β = 106.23°, γ = 90°, and the unit cell volume is 1798.7 Å. 3 It is. 1.4 DSC of 1:1 psilocin benzoate 1 A differential scanning calorimetry (DSC) trace (Figure 3) shows a single endotherm with a peak maximum at about 237°C corresponding to the melting of the salt. 1.5 TGA of 1:1 psilocin benzoate 1 Thermogravimetric analysis (TGA) traces (Figure 4) show no significant mass loss prior to the melting temperature of this salt, around 200°C. 1.6 1:1 psilocin benzoate, 1 1 H NMR spectrum Figure 5 shows the 1:1 psilocin benzoate 1 The H NMR spectrum shows the following peaks: 1H NMR (600MHz, CD3OD) δ: 7.95 (2H), 7.34~7.42 (3H), 6.99 (1H), 6.83~6.90 (2H), 6.37 (1H), 3.40 (2H), 3.25 (2H), and 2.83 (6H). 1 The H NMR spectrum shows a multiplet at 6.37 ppm corresponding to one proton in psilocin. Comparing the integral of this peak with the multiplet at 7.95 ppm corresponding to two aromatic ring protons in benzoic acid indicates that the salt has a 1:1 psilocin:benzoate stoichiometry.
[0018] [Example 2] 1:1 Psilocin Nicotinate 2 2.1 Preparation of 1:1 psilocin nicotinate salt 2 A solution containing 207.1 mg of psilocin (Cayman Chemical, lot: 0594443) in 10 mL of isopropyl alcohol (Fisher Scientific, lot: 182481) was prepared at 60°C. The solution was decolorized with activated charcoal and filtered through a 0.2 μm nylon filter. A 5 mL aliquot of the clear solution was added to 60.7 mg of nicotinic acid (Sigma Aldrich, lot: SLBH9954V). The suspension was heated briefly to 60°C to ensure complete dissolution. The clear solution was refrigerated for 1 day and stored in the freezer for an additional 5 days. The precipitate was isolated by water suction vacuum filtration and briefly dried under a nitrogen purge. 2.2 XRPD Characterization of 1:1 Psilocin Nicotinate 2 The experimental XRPD pattern of the 1:1 psilocin nicotinate salt 2 is shown in Figure 6. Table 2 shows the angles (°2θ±0.2°2θ) and interplanar spacings of the peaks identified in the experimental XRPD pattern of Figure 6. The entire list of peaks, or a subset thereof, may be sufficient to characterize the salt, as well as an XRPD pattern substantially similar to Figure 6 (i.e., discernible within experimental variability by one skilled in the art using the present methods). For example, the 1:1 psilocin nicotinate salt of the present invention may be characterized by a powder X-ray diffraction pattern having at least 3, 4, or 5 peaks selected from 10.2, 11.4, 12.4, 14.0, 15.1, 15.6, 17.2, 17.5, 18.4, 19.2, 20.0, 22.4, 23.5, 24.1, 25.0, and 25.2°2θ±0.2°2θ. [Table 2] 2.3 Indexing of the XRPD pattern of 1:1 psilocin nicotinate 2 The XRPD indexing description (Figure 7) is P1(1) or The triclinic crystal system has space group TIFF0007594330000014.tif9160. The unit cell parameters are a = 9.343 Å, b = 9.595 Å, c = 11.079 Å, α = 76.04°, β = 71.26°, γ = 74.13°, and the unit cell volume is 891.7 Å. 3 It is. 2.4 DSC of 1:1 psilocin nicotinate 2 A differential scanning calorimetry (DSC) trace (Figure 8) shows a single endotherm with a peak maximum at about 189°C corresponding to the melting of the salt. 2.5 TGA of 1:1 psilocin nicotinate 2 The thermogravimetric analysis (TGA) trace (Figure 9) shows no significant mass loss prior to the melting temperature of this salt, around 187°C. 2.6 1:1 psilocin nicotinate 2 1 H NMR spectrum The 1:1 psilocin nicotinate salt shown in FIG. 1 The H NMR spectrum shows the following peaks: 1H NMR (600MHz, CD3OD) δ: 9.06(1H), 8.53(1H), 8.31(1H), 7.43(1H), 7.01(1H), 6.83~6.90(2H), 6.37(1H), 3.48(2H), 3.26(2H), and 2.89(6H). 1 The H NMR spectrum shows a multiplet at 6.37 ppm corresponding to one proton of psilocin. Comparing the integral of this peak with the multiplet at 9.06 ppm corresponding to one aromatic ring proton of nicotinic acid indicates that the salt has a 1:1 psilocin:nicotinate stoichiometry.
[0019] [Example 3] 1:1 Psilocin Tartrate 3 3.1 Preparation of 1:1 psilocin tartrate 3 A solution of 69.6 mg of psilocin (Cayman Chemical, lot: 0594443) in 2 mL of acetone (Fisher Scientific, lot: 494118) was decolorized with activated charcoal and filtered through a 0.2 μm nylon filter. The clear solution was added to 50.1 mg of L-(+)-tartaric acid (Sigma Aldrich, lot: BCBT1076) to give a cloudy suspension. An additional 2 mL of acetone was added and the suspension was allowed to slurried at room temperature for 6 days. The precipitate was isolated by water suction vacuum filtration. 3.2 XRPD Characterization of 1:1 Psilocin Tartrate 3 The experimental XRPD pattern of the 1:1 psilocin tartrate salt 3 is shown in Figure 11. Table 3 shows the angles (°2θ±0.2°2θ) and interplanar spacings of the peaks identified in the experimental XRPD pattern of Figure 11. The entire list of peaks, or a subset thereof, may be sufficient to characterize the salt, as may an XRPD pattern substantially similar to Figure 11 (i.e., discernible within experimental variability by one of ordinary skill in the art using the present methods). For example, the 1:1 psilocin tartrate salt of the present invention may be characterized by a powder X-ray diffraction pattern having at least three, four, or five peaks selected from 13.4, 14.7, 15.9, 17.2, 18.8, 20.2, 20.8, 21.8, 22.6, 23.4, 24.6, 24.8, 25.5, and 26.6°2θ±0.2°2θ. [Table 3] TIFF0007594330000016.tif114152 3.3 Indexing of the XRPD pattern of 1:1 psilocin tartrate 3 The XRPD indexing description (Figure 12) shows a basic orthorhombic crystal system with a space group of P212121(19). The unit cell parameters are a = 7.588 Å, b = 8.236 Å, c = 26.409 Å, α = 90°, β = 90°, γ = 90°, and the unit cell volume is 1650.4 Å. 3 It is. 3.4 DSC of 1:1 psilocin tartrate 3 A differential scanning calorimetry (DSC) trace (Figure 13) shows a single endotherm with a peak maximum at about 167°C corresponding to the melting of the salt. 3.5 TGA of 1:1 psilocin tartrate 3 The thermogravimetric analysis (TGA) trace (Figure 14) shows no significant mass loss prior to the melting temperature of this salt, around 164°C. 3.6 1:1 psilocin tartrate 3 1 H NMR spectrum The 1:1 psilocin tartrate shown in FIG. 1 The H NMR spectrum shows the following peaks: 1 H NMR (600MHz, CD3OD) δ: 7.02 (1H), 6.85~6.90 (2H), 6.37 (1H), 4.41 (2H), 3.48 (2H), 3.27~3.31 (2H), and 2.90 (6H). 1 The H NMR spectrum shows a multiplet at 6.37 ppm corresponding to one proton in psilocin. Comparing the integral of this peak with the singlet at 4.41 ppm corresponding to two protons in the tartrate salt indicates that the salt has a 1:1 psilocin:tartrate stoichiometry.
[0020] [Example 4] 2:1 Hemiacetone solvate of psilocin hemiadipate 4 4.1 Preparation of the 2:1 hemiacetone solvate of psilocin hemiadipate 4 A solution of 62.4 mg of psilocin (Cayman Chemical, Lot: 0594443) in 2 mL of acetone (Fisher Scientific, Lot: 494118) was decolorized with activated charcoal and filtered through a 0.2 μm nylon filter. The clear solution was added to 43.6 mg of adipic acid (Sigma Aldrich, Lot: MKBP7307V) to form an oil. The oil suspension was allowed to slurried at room temperature for 6 days until precipitation occurred. The precipitate was isolated by water suction vacuum filtration. 4.2 XRPD Characterization of the 2:1 Psilosin Hemiadipic Acid Hemiacetone Solvate 4 The experimental XRPD pattern of the hemiacetone solvate of 2:1 psilocin hemiadipate salt 4 is shown in Figure 16. Table 4 provides the angles (°2θ±0.2°2θ) and interplanar spacings of the peaks identified in the experimental XRPD pattern of Figure 16. The entire list of peaks, or a subset of these, may be sufficient to characterize a salt, as well as an XRPD pattern substantially similar to Figure 16 (i.e., discernible within experimental variability by one of ordinary skill in the art using the present methods). For example, the 2:1 psirosin hemiadipate hemiacetone solvate of the present invention may be characterized by an X-ray powder diffraction pattern having at least three, four, or five peaks selected from 8.4, 10.3, 10.8, 13.4, 15.0, 15.3, 15.5, 15.8, 16.9, 18.2, 20.1, 21.6, 21.8, 22.9, and 28.0 °2θ±0.2 °2θ. [Table 4] 4.3 Indexing of the XRPD pattern of the 2:1 psilocin hemiadipate 4 hemiacetone solvate The XRPD indexing description (Figure 17) shows a basic orthorhombic crystal system with a space group of Pbcn(60). The unit cell parameters are a = 11.826 Å, b = 22.402 Å, c = 13.236 Å, α = 90°, β = 90°, γ = 90°, and the unit cell volume is 3506.6 Å. 3 It is. 4.4 DSC of the 2:1 hemiacetone solvate of psilocin hemiadipate 4 A differential scanning calorimetry (DSC) trace (Figure 18) shows multiple endotherms with peak maxima at about 49, 102, 135, and 155°C, in addition to a single endotherm with a peak maximum at about 179°C. 4.5 TGA of the 2:1 hemiacetone solvate of psilocin hemiadipate 4 The thermogravimetric analysis (TGA) trace (Figure 19) shows a weight loss of about 8% up to about 166°C, which is likely the loss of acetone that is part of the crystal lattice. 4.6 2:1 Hemiacetone solvate of psilocin hemiadipate 4 1 H NMR spectrum The 2:1 psilocin hemiadipate hemiacetone solvate shown in FIG. 1 The H NMR spectrum shows the following peaks: 1 H NMR (600MHz, CD3OD) δ:6.97(1H), 6.83~6.90(2H), 6.36(1H), 3.28~3.30(2H ), 3.20~3.22(2H), 2.75(6H), 2.20~2.25(2H), 2.15(3H), and 1.63~1.67(2H). 1 The H NMR spectrum shows a multiplet at 6.36 ppm, which corresponds to one proton in psilocin. Comparing the integral of this peak with the integral of the multiplet at 1.63-1.67 ppm, which corresponds to two protons in adipic acid, indicates that the salt has a psilocin:adipate stoichiometry of 2:1. Furthermore, comparing the integral of the singlet at 2.15 ppm, which corresponds to three protons in acetone, indicates that the salt contains 0.5 equivalents of acetone solvent.
[0021] [Example 5] 1:1 Silosin Fumarate 5 5.1 Preparation of 1:1 psilocin fumarate 5 A solution of 60.7 mg of psilocin (Cayman Chemical, lot: 0594443) in 2 mL of acetone (Fisher Scientific, lot: 494118) was decolorized with activated charcoal and filtered through a 0.2 μm nylon filter. The clear solution was added to 32.6 mg of fumaric acid (Sigma Aldrich, lot: MKBB7131) and precipitated rapidly. The suspension was allowed to slurried at room temperature for 6 days. The precipitate was isolated by water suction vacuum filtration. 5.2 XRPD Characterization of 1:1 Psilosin Fumarate 5 The experimental XRPD pattern for 1:1 silosin fumarate 5 is shown in Figure 21. Table 5 provides the angles (°2θ±0.2°2θ) and interplanar spacings of the peaks identified in the experimental XRPD pattern of Figure 21. The entire list of peaks, or a subset of these, may be sufficient to characterize a salt, as well as an XRPD pattern substantially similar to Figure 21 (i.e., discernible within experimental variability by one of ordinary skill in the art using the present methods). For example, the 1:1 psirosin fumarate of the present invention may be characterized by an X-ray powder diffraction pattern having at least three, four, or five peaks selected from 6.9, 10.5, 12.2, 12.6, 15.8, 16.1, 16.7, 17.0, 18.3, 19.1, 20.3, 20.8, 22.6, 23.1, 23.3, 23.5, 24.2, 25.3, 25.9, and 27.8 °2θ±0.2 °2θ. [Table 5] 5.3 Indexing of the XRPD pattern of 1:1 Silosin Fumarate 5 The XRPD indexing description (Figure 22) shows a basic monoclinic crystal system with a space group of P21 / n(14). The unit cell parameters are a = 7.441 Å, b = 8.877 Å, c = 25.707 Å, α = 90°, β = 93.34°, γ = 90°, and the unit cell volume is 1695.2 Å. 3 It is. 5.4 DSC of 1:1 Silosin Fumarate 5 A differential scanning calorimetry (DSC) trace (Figure 23) shows a pronounced endotherm with a peak maximum at about 167°C, corresponding to the melting of the salt. 5.5 TGA of 1:1 Silosin Fumarate 5 The thermogravimetric analysis (TGA) trace (Figure 24) shows negligible mass loss of less than 0.4% before the onset of melting temperature of this salt, around 166°C. 5.6 1:1 Silosin Fumarate 5 1 H NMR spectrum The 1:1 silosin fumarate salt shown in FIG. 1 The H NMR spectrum shows the following peaks: 1 H NMR (600MHz, CD3OD) δ: 7.02 (1H), 6.84~6.92 (2H), 6.69 (2H), 6.38~6.36 (1H), 3.49 (2H), 3.28 (2H), 2.90 (6H). 1 The H NMR spectrum shows a multiplet at 6.38-6.36 ppm, corresponding to one proton in psilocin. Comparing the integral of this peak with the singlet at 6.69 ppm, corresponding to two protons in fumaric acid, indicates that the psilocin:fumarate stoichiometry of this salt is 1:1.
[0022] [Example 6] 2:1 Silosin Hemifumarate 6 6.1 Preparation of 2:1 psilocin hemifumarate 6 A solution containing 90.8 mg of psilocin (Cayman Chemical, lot: 0594443) in 2 mL of acetone (Fisher Scientific, lot: 494118) was decolorized with activated charcoal and filtered through a 0.2 μm nylon filter. This room temperature solution was turned oily by the addition of a 60°C suspension containing 51.1 mg of fumaric acid (Sigma Aldrich, lot: MKBB7131) in 3 mL of acetone (Fisher Scientific, lot: 494118). This oily suspension was seeded with 1:1 psilocin fumarate salt 5 and precipitated by sonication for 30 seconds. The precipitate was isolated by water suction vacuum filtration, washed with 2 mL of acetone (Fisher Scientific, lot: 494118), and briefly dried under a nitrogen purge. 6.2 XRPD Characterization of 2:1 Psilocin Hemifumarate 6 The experimental XRPD pattern of 2:1 psilocin hemifumarate 6 is shown in Figure 26. Table 6 shows the angles (°2θ±0.2°2θ) and interplanar spacings of the peaks identified in the experimental XRPD pattern of Figure 26. The entire list of peaks, or a subset thereof, may be sufficient to characterize the salt, as may an XRPD pattern substantially similar to Figure 26 (i.e., discernible within experimental variability by one skilled in the art using the present methods). For example, the 2:1 psilocin hemifumarate of the present invention may be characterized by a powder X-ray diffraction pattern having at least 3, 4, or 5 peaks selected from 9.7, 13.7, 16.1, 16.6, 23.9, 24.7, and 25.2°2θ±0.2°2θ. Other peaks at approximately 10.5, 12.6, 18.3, 19.1, and 20.8 degrees 2θ were not due to the 2:1 psirosin fumarate salt, as they matched peaks corresponding to the 1:1 psirosin fumarate salt component. [Table 6] 6.3 Indexing of the XRPD pattern of 2:1 psilocin hemifumarate 6 The XRPD indexing description (Figure 27) is P1(1) or The triclinic crystal system has the space group TIFF0007594330000020.tif9160. The unit cell parameters are a = 8.118 Å, b = 9.361 Å, c = 9.396 Å, α = 101.03°, β = 96.64°, γ = 102.18°, and the unit cell volume is 676.0 Å. 3 It is. 6.4 DSC of 2:1 psilocin hemifumarate 6 The Differential Scanning Calorimetry (DSC) trace (Figure 28) shows minor endotherms near 149 and 166°C. The weak endotherm observed near 166°C is consistent with the melting of the 1:1 syrosin fumarate component. The final endotherm with an onset at approximately 225°C is due to the melting of the 2:1 syrosin hemifumarate. 6.5 TGA of 2:1 psilocin hemifumarate 6 The thermogravimetric analysis (TGA) trace (Figure 29) shows no significant mass loss prior to the melting temperature of this salt, near 225°C. 6.6 2:1 Silicosin Hemifumarate 6 1 H NMR spectrum The 2:1 silosin hemifumarate salt shown in FIG. 1 The H NMR spectrum shows the following peaks: 1 H NMR (600MHz, CD3OD) δ: 6.99 (1H), 6.90~6.83 (2H), 6.69 (1H), 6.37~6.36 (1H), 3.40 (2H), 3.25 (2H), and 2.83 (6H). 1 The H NMR spectrum shows a multiplet at 6.37-6.36 ppm corresponding to one proton of psilocin. Comparing the integral of this peak with the singlet at 6.69 ppm corresponding to the protons of fumaric acid indicates that the psilocin:fumarate stoichiometry of this salt is 2:1.
[0023] [Example 7] 1:1 Solvate of Siloxane Oxalate 7 7.1 Preparation of the 1:1 solvate of psilocin oxalate 7 A solution containing 216.5 mg of psilocin (Cayman Chemical, Lot: 0594443) in 15 mL of 80:20 v / v diethyl ether / ethanol (Sigma Aldrich, Lots: SHBL6577 and SHBK9943, respectively) was decolorized with activated charcoal and filtered through a 0.2 μm nylon filter. A 5 mL aliquot of the clear solution was added to 31.3 mg of oxalic acid (Sigma Aldrich, Lot: SHBC7057V), resulting in a cloudy suspension. The suspension was allowed to slurried at room temperature for 1 day. The precipitate was isolated by water suction vacuum filtration. 7.2 XRPD Characterization of the 1:1 Psilocin Oxalate 7 Solvate The experimental XRPD pattern of the 1:1 psilocin oxalate 7 solvate is shown in Figure 31. Table 7 lists the angles (°2θ±0.2°2θ) and spacings of the peaks identified in the experimental XRPD pattern of Figure 31. The entire list of peaks, or a subset of these, may be sufficient to characterize a salt, as well as an XRPD pattern substantially similar to Figure 31 (i.e., discernible within experimental variability by one of ordinary skill in the art using the present methods). For example, the 1:1 syrosine oxalate solvates of the present invention may be characterized by an X-ray powder diffraction pattern having at least three, four, or five peaks selected from 7.6, 7.8, 10.3, 14.2, 15.3, 15.7, 17.1, 19.5, 20.4, 20.6, 21.0, 21.7, 22.9, 23.7, 24.1, 24.3, 24.8, and 27.1 °2θ±0.2 °2θ. [Table 7] 7.3 Indexing of XRPD patterns of 1:1 psilocin oxalate 7 solvates The XRPD indexing description (Figure 32) shows a basic monoclinic crystal system with a space group of P21 / n(14). The unit cell parameters are a = 5.690 Å, b = 12.894 Å, c = 23.273 Å, α = 90°, β = 96.83°, γ = 90°, and the unit cell volume is 1695.3 Å. 3 The XRPD pattern of 7 can be successfully indexed with a single unit cell, providing strong evidence that the pattern represents a single crystalline phase. The unit cell likely contains four psilocin cations and four oxalate anions. Therefore, the formula unit volume calculated from the indexing results is 424 Å. 3 is about 58 Å, which can partially accommodate the solvent. 3 This may result in a free volume of 7.4 DSC of 1:1 psilocin oxalate 7 solvate The differential scanning calorimetry (DSC) trace (Figure 33) shows multiple endothermic events between 80 and 160°C that are likely due to the evaporation of the solvent. 7.5 TGA of 1:1 psilocin oxalate 7 solvate The thermogravimetric analysis (TGA) trace (Figure 34) shows a mass loss of about 6% by 149°C, which is likely due to the loss of diethyl ether and ethanol solvents that are part of the crystal lattice. This mass loss is consistent with the combined volatilization of 0.2 mol / mol diethyl ether and 0.1 mol / mol ethanol. 7.6 1:1 Solvate of Siloxane Oxalate 7 1 H NMR spectrum As shown in Figure 35 1 The H NMR spectrum shows the following peaks: 1 H NMR (600MHz, CD3OD) δ: 7.02 (1H), 6.84~6.90 (2H), 6.36~6.37 (1H), 3.47~3.51 (2H), 3.27~3.29 (2H), and 2.90 (6H). 1 The H NMR spectrum shows a multiplet at 6.36-6.37 ppm, which corresponds to one proton in psilocin. Comparing the integrals of the solvent peaks to the multiplet at 6.36-6.37 ppm, which corresponds to one proton in psilocin, indicates that the salt contains approximately 0.2 mol / mol diethyl ether and 0.1 mol / mol ethanol. 7.7 Ion chromatography of the 1:1 solvate of psilocin oxalate 7 The anion content of the samples was analyzed using the ion chromatography method described above to quantify the anions in the samples. Ion chromatographic analysis of the 1:1 psilocin oxalate 7 solvate revealed the presence of oxalate ions, indicating that this salt is a monooxalate salt.
[0024] [Example 8] 1:1 Psilocin DL-Lactate 8 8.1 Preparation of 1:1 Psilocin DL-Lactate 8 24.7 mg of psilocin (Cayman Chemical) was mixed with 5 mL of diethyl ether in a 1 dram glass vial. Complete dissolution was observed and activated charcoal was added to the vial. The sample was then sonicated and filtered through a 0.45 μm filter into a vial containing 12.0 mg of D,L-lactic acid (1 molar equivalent). A white solid formed and the sample was stirred at 50°C for 4 days. The sample was cooled to room temperature and centrifuged, after which the supernatant was decanted. The solid was allowed to air dry. 8.2 XRPD Characterization of 1:1 Psilocin DL-Lactate 8 The experimental XRPD pattern of 1:1 psilocin DL-lactate 8 is shown in Figure 36. Table 8 shows the angles (°2θ±0.2°2θ) and interplanar spacings of the peaks identified in the experimental XRPD pattern of Figure 36. The entire list of peaks, or a subset thereof, may be sufficient to characterize the salt, as may an XRPD pattern substantially similar to Figure 36 (i.e., discernible within experimental variability by one skilled in the art using the present methods). For example, the 1:1 psilocin DL-lactate of the present invention may be characterized by a powder X-ray diffraction pattern having at least 3, 4, or 5 peaks selected from 9.0, 13.8, 14.4, 15.6, 17.8, 18.4, 20.3, 21.7, 22.3, 22.9, 24.0, and 25.5°2θ±0.2°2θ. [Table 8] 8.3 Indexing the XRPD Pattern of 1:1 Psilocin DL-Lactate 8 The XRPD indexing description (Figure 37) shows a basic monoclinic crystal system with a space group of P21 / c(14). The unit cell parameters are a = 11.787 Å, b = 8.473 Å, c = 18.455 Å, α = 90°, β = 56.30°, γ = 90°, and the unit cell volume is 1533.5 Å. 3 It is. 8.4 DSC of 1:1 Psilocin DL-Lactate 8 The differential scanning calorimetry (DSC) trace (Figure 38) shows a single endotherm with a peak maximum at about 148°C corresponding to the melting / decomposition of the salt. 8.5 TGA of 1:1 Psilocin DL-lactate 8 The thermogravimetric analysis (TGA) trace (Figure 39) shows a 1.7% mass loss by 135°C, likely due to the loss of DL-lactic acid (boiling point approximately 122°C). 8.6 1:1 Psilocin DL-lactate 8 1 H NMR spectrum The 1:1 psilocin DL-lactate salt shown in FIG. 1 The H NMR spectrum shows the following peaks: 1 H NMR (400MHz, DMSO-D6) δ: 10.61(1H), 6.93(1H), 6.73~6.81(2H), 6.27(1H), 3.90~3.95(1H), 2.93(2H), 2.70(2H), 2.34(6H), and 1.19(3H). 1 The H NMR spectrum shows a multiplet at 6.27 ppm corresponding to one proton in psilocin. Comparing the integral of this peak with the integral of the multiplet at 1.19 ppm corresponding to the three methyl protons in DL-lactic acid, indicates that the salt has a 1:1 psilocin:DL-lactate stoichiometry.
[0025] [Example 9] 1:1 Psilocin L-Malate 9 9.1 Preparation of 1:1 Psilocin L-Malate 9 24.7 mg of psilocin (Cayman Chemical) was mixed with 1 mL of methyl ethyl ketone in a 1 dram glass vial. Complete dissolution was observed and activated charcoal was added to the vial. The sample was then sonicated and filtered through a 0.45 μm filter into a new vial containing 16.2 mg of L-malic acid (1 molar equivalent). The sample was stirred at room temperature for 7 days. The sample was centrifuged and the supernatant was decanted. The solid was allowed to air dry. 9.2 XRPD Characterization of 1:1 Psilocin L-Malate 9 The experimental XRPD pattern of 1:1 psilocin L-malate 9 is shown in Figure 41. Table 9 shows the angles (°2θ±0.2°2θ) and interplanar spacings of the peaks identified in the experimental XRPD pattern of Figure 41. The entire list of peaks, or a subset thereof, may be sufficient to characterize the salt, as may an XRPD pattern substantially similar to Figure 41 (i.e., discernible within experimental variability by one of ordinary skill in the art using the present methods). For example, the 1:1 psilocin L-malate of the present invention may be characterized by a powder X-ray diffraction pattern having at least three peaks selected from 8.6, 9.0, 11.7, 12.6, 15.9, 16.8, 18.1, 20.2, 20.6, 21.4, 22.8, 26.1, and 28.0°2θ±0.2°2θ. [Table 9] 9.3 Indexing of the XRPD pattern of 1:1 Psilocin L-Malate 9 The XRPD indexing description (Figure 42) shows a basic monoclinic crystal system with a space group of P21(4). The unit cell parameters are a = 7.558 Å, b = 11.151 Å, c = 20.520 Å, α = 90°, β = 92.15°, γ = 90°, and the unit cell volume is 1728.3 Å. 3 It is. 9.4 DSC of 1:1 Psilocin L-Malate 9 A differential scanning calorimetry (DSC) trace (Figure 43) shows a single endotherm with a peak maximum at about 129°C corresponding to the melting of the salt. 9.5 TGA of 1:1 Psilocin L-Malate 9 The thermogravimetric analysis (TGA) trace (Figure 44) shows no significant mass loss until around 125°C. 9.6 1:1 Psilocin L-Malate 9 1 H NMR spectrum The 1:1 psilocin L-malate salt shown in FIG. 1 The H NMR spectrum shows the following peaks: 1H NMR (400 MHz, DMSO-D6) δ: 10.73 (1H), 7.01 (1H), 6.80-6.84 (2H), 6.32 (1H), 3.92 (1H), 3.07-3.14 (4H), 2.67 (6H), and 2.30-2.35 (1H). 1 The H NMR spectrum shows a multiplet at 6.32 ppm corresponding to one proton in psilocin. Comparing the integral of this peak with the multiplet at 3.92 ppm corresponding to one proton in malic acid indicates that the salt has a 1:1 psilocin:malate stoichiometry.
[0026] [Example 10] 1:1 Syrosin Stearate 10 10.1 Preparation of 1:1 psilocin stearate 10 24.7 mg of silosin (Cayman Chemical) and 33.8 mg of stearic acid (1 molar equivalent) were mixed in a PEEK grinding cup. 10 μL of 50:50 methyl tert-butyl ether / hexane and a stainless steel ball were added to the cup. The PEEK grinding cup was capped and placed in a Retsch Mill MM200 and milled at 100% power for 30 minutes. The resulting solids were collected and analyzed. 10.2 XRPD Characterization of 1:1 Syrosin Stearate 10 The experimental XRPD pattern of 1:1 syrosine stearate 10 is shown in Figure 46. Table 10 shows the angles (°2θ±0.2°2θ) and interplanar spacings of the peaks identified in the experimental XRPD pattern of Figure 46. The entire list of peaks, or a subset thereof, may be sufficient to characterize the salt, as well as an XRPD pattern substantially similar to Figure 46 (i.e., discernible within experimental variability by one skilled in the art using the present methods). For example, the 1:1 syrosine stearate of the present invention may be characterized by a powder X-ray diffraction pattern having at least three peaks selected from 4.5, 8.9, 14.4, 15.6, 20.1, 21.0, 23.9, and 26.4°2θ±0.2°2θ. [Table 10] 10.3 Indexing the XRPD pattern of 1:1 Syrosin Stearate 10 The XRPD indexing description (Figure 47) shows a fundamental triclinic crystal system with space group P1(1) or P-1(2). The unit cell parameters are a = 7.726 Å, b = 11.747 Å, c = 20.293 Å, α = 77.79°, β = 96.28°, γ = 122.75°, and the unit cell volume is 1513.96 Å. 3 It is. 10.4 DSC of 1:1 Syrosin Stearate 10 The differential scanning calorimetry (DSC) trace (Figure 48) shows a single endotherm with a peak maximum at about 86°C corresponding to the melting of the salt. 10.5 TGA of 1:1 Syrosin Stearate 10 The thermogravimetric analysis (TGA) trace (Figure 49) shows no significant mass loss up to 85°C. 10.6 1:1 Siloxane Stearate 10 1 H NMR spectrum The 1:1 silosin stearate shown in FIG. 1 The H NMR spectrum shows the following peaks: 1 H NMR (400MHz, DMSO-D6) δ: 10.58 (1H), 6.90 (1H), 6.72~6.80 (2H), 6.25 (1H), 2 .87(2H), 2.55(2H), 2.22(6H), 2.17(2H), 1.46(2H), 1.23(29H), and 0.85(3H). 1 The H NMR spectrum shows a multiplet at 6.25 ppm corresponding to one proton in psilocin. Comparing the integral of this peak with the integral of the multiplet at 0.85 ppm corresponding to the three protons in the methyl groups of stearic acid indicates that the salt has a 1:1 psilocin:stearate stoichiometry.
Claims
1. A crystalline salt or co-crystal of stearic acid and psilocin (4-hydroxy-N,N-dimethyltryptamine) having a 1:1 stoichiometry and exhibiting an X-ray powder diffraction pattern with at least three peaks at the following 2θ diffraction angles: 4.5, 8.9, 14.4, 15.6, 20.1, 21.0, 23.9, and 26.4°2θ±0.2°2θ.
2. 2. The crystalline salt or co-crystal of claim 1, wherein the crystalline salt or co-crystal has an X-ray powder diffraction pattern with all peaks at the following 2θ diffraction angles: 4.5, 8.9, 14.4, 15.6, 20.1, 21.0, 23.9, and 26.4 °2θ±0.2 °2θ.
3. The crystalline salt or co-crystal comprises a crystal having unit cell parameters equal to: [Table 10] 2. The crystalline salt or co-crystal of claim 1.
4. The crystalline salt or co-crystal has the following characteristics: an endothermic event with a peak maximum at 86° C. as measured by differential scanning calorimetry; A thermogravimetric analysis thermogram showing no mass loss up to 85° C.; or d including one or more chemical shift peaks at 0.9 ppm, 1.2 ppm, 1.5 ppm, 2.2 ppm, 2.6 ppm, 2.9 ppm, 6.3 ppm, 6.7 ppm, 6.8 ppm, 6.9 ppm, and 10.6 ppm 6 -DMSO solution 1 H NMR spectrum The crystalline salt or co-crystal of claim 1, further comprising one or more of:
5. 5. The crystalline salt or co-crystal of claim 4, wherein the crystalline salt or co-crystal has a differential scanning calorimetry thermogram showing a single endotherm with a peak maximum at 86° C. corresponding to melting of the salt.
6. The crystalline salt or co-crystal contains characteristic chemical shift peaks at at least 6.3 ppm and 0.9 ppm. 6-DMSO solution 1 5. The crystalline salt or co-crystal of claim 4 having a H NMR spectrum.
7. A solution in which the crystalline salt or co-crystal contains all chemical shift peaks at 0.9 ppm, 1.2 ppm, 1.5 ppm, 2.2 ppm, 2.6 ppm, 2.9 ppm, 6.3 ppm, 6.7 ppm, 6.8 ppm, 6.9 ppm, and 10.6 ppm. 1 5. The crystalline salt or co-crystal of claim 4 having a H NMR spectrum.
8. 13. A pharmaceutical composition comprising the crystalline salt or co-crystal of claim 1 and at least one pharma- ceutically acceptable carrier.
9. The pharmaceutical composition of claim 8 , wherein the pharmaceutical composition is an oral formulation.
10. 10. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is an oral solid dosage form.
11. 13. A method for preparing the crystalline salt or co-crystal of claim 1, comprising reacting stearic acid with psilocin to precipitate a salt or co-crystal of psilocin and stearic acid in crystalline form.
12. 12. The method of claim 11, further comprising dissolving or suspending or grinding the silosin and / or stearic acid in an organic solvent selected from the group consisting of alcohols, ethers, ketones, alkanes, and mixtures thereof.
13. 13. The method of claim 12, wherein the organic solvent is diethyl ether, isopropyl alcohol, acetone, ethanol, methyl ethyl ketone, methyl tert-butyl ether, hexane, or a mixture thereof.
14. 10. The pharmaceutical composition of claim 8, for use in a method of treating a disease or disorder in a subject in need thereof, comprising administering a therapeutically effective amount of the crystalline salt or co-crystal of claim 1 to the subject in need thereof, wherein the disease or disorder is a psychiatric or psychotic disorder, a neurocognitive disease or disorder, an autism spectrum disorder (ASD), chronic pain, an inflammatory disease or disorder, stroke, an epilepsy disorder, amyotrophic lateral sclerosis (ALS), or a combination thereof.
15. 15. The pharmaceutical composition of claim 14, wherein the disease or disorder is a psychiatric or psychotic disorder selected from the group consisting of attention deficit hyperactivity disorder (ADHD), anxiety disorder, sleep-wake disorder, impulse control disorder, disruptive behavior disorder, conduct disorder, depressive disorder, major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder and related disorders, bipolar disorder, schizophrenia, and combinations thereof.
16. 15. The pharmaceutical composition of claim 14, wherein the disease or disorder is a neurocognitive disease or disorder selected from the group consisting of Alzheimer's disease; dementia with Lewy bodies; traumatic brain injury; prion disease; HIV infection; Parkinson's disease; Huntington's disease; and combinations thereof.
17. The method of claim 13, wherein the organic solvent is a mixture of methyl tert-butyl ether and hexane.
18. 18. The method of claim 17, wherein the organic solvent is a 50:50 mixture of methyl tert-butyl ether:hexane.
Citation Information
Patent Citations
4-hydroxytryptamines
GB912715A
Method of inducing therapeutic tranquilization with psilocybin and psilocin
US3192111A
